ARCHIVES

DC Board Okay One Recompetition, Disapproves Two

This article is from The Cancer Letter archive.

Vol. 08 No. 44 | November 12, 1982

Download PDF Visit The Full Archive

Related Articles

Scientists, advocates voice objections to von Eschenbach’s conflicts, 2015.

November 23, 2005

Tamoxifen: No Mortality Benefit For Most “High Risk” Women

September 29, 2006

Statins Associated With Lower Risk Of High-Grade Prostate Cancer

March 25, 2011

Cancer Epidemiology Hampered By Bureaucratic Delays, Lack of Cooperation, NCI Group Says

September 29, 1978

EU Gives Marketing Approval For HBV Sequencing Test

April 29, 2011

Two Private Cancer Information Services Are Up and Running

May 13, 1988